You are here

Keytruda

The FDA Has Never Approved a Drug Like This in Its 111-Year History

The FDA Has Never Approved a Drug Like This in Its 111-Year History

Motley Fool

mismatch repair deficiency

Flag link:

Could Merck and Leap union be the one for Keytruda?

Could Merck and Leap union be the one for Keytruda?

TheStreet.com

Leap Therapeutics

esophagogastric cancer

Flag link:

Checkmate Pharma Clinches $27M for More Studies in Skin Cancer

Checkmate Pharma Clinches $27M for More Studies in Skin Cancer

Xconomy

Checkmate Pharmaceuticals

Flag link:

Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research

Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research

Endpoints

Flag link:

Merck pauses Keytruda trials, raising concerns about class

Merck pauses Keytruda trials, raising concerns about class

BioPharma Dive

clinical trials

Flag link:

How Merck hopes to win in I/O combos: Q&A with Roy Baynes

How Merck hopes to win in I/O combos: Q&A with Roy Baynes

BioPharma Dive

immuno-oncology

Bristol-Myers Squibb

Flag link:

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

Endpoints

clinical trials

Multiple Myeloma

Flag link:

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

Endpoints

Bristol-Myers Squibb

Flag link:

Why Array BioPharma Inc. Sank 13.5% in May

Why Array BioPharma Inc. Sank 13.5% in May

Motley Fool

Array Biopharma

Bristol-Myers Squibb

Flag link:

An Unprecedented FDA Approval Bodes Well for this Drug Stock

An Unprecedented FDA Approval Bodes Well for this Drug Stock

Motley Fool

Flag link:

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

BioPharma Dive

Flag link:

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

Endpoints

non-small cell lung cancer

Flag link:

How Did Bristol Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss

How Did Bristol Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss

Forbes

Bristol-Myers Squibb

Flag link:

The immuno-oncology market prepares for the inevitable question: 'What's next?'

The immuno-oncology market prepares for the inevitable question: 'What's next?'

Medical Marketing and Media

immuno-oncology

Bristol-Myers Squibb

Flag link:

On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy

On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy

Xconomy

Bristol-Myers Squibb

Flag link:

Here's How the FDA Just Helped Trump Deliver on a Big Promise

Here's How the FDA Just Helped Trump Deliver on a Big Promise

Motley Fool

Flag link:

Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker

Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker

Endpoints

Flag link:

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

Endpoints

Flag link:

Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo

Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo

Endpoints

non-small cell lung cancer

Flag link:

AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next

AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next

Forbes

Flag link: